UPDATE -- NPS Pharmaceuticals, Inc. [NPSP] to Ring The NASDAQ Stock Market Opening Bell
November 04 2011 - 7:39PM
ADVISORY, Nov. 4, 2011 (GLOBE NEWSWIRE) --
What:
NPS Pharmaceuticals (Nasdaq:NPSP) a biopharmaceutical company
focused on bringing orphan products to patients with rare disorders
and few, if any, therapeutic options, will visit the NASDAQ
MarketSite in New York City's Times Square.
In honor of the occasion Francois Nader, President & CEO
will ring the Opening Bell.
Where:
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway –
Broadcast Studio
When:
Monday, November 7th, 2011 – 9:15 a.m. to 9:30 a.m.
ET
Contacts:
Tony Plohoros 6 Degrees PR (908) 591.2839
(mobile) tplohoros@6degreesPR.com
Susan Mesco NPS Pharmaceuticals (908) 391-8283
smesco@npsp.com
NASDAQ MarketSite:
Jen Knapp (212) 401-8916
Jennifer.knapp@nasdaqomx.com
Feed Information:
Fiber Line (Encompass Media): 4463 Can also be found on
Satellite: Gal 3C/06C 95.05 degrees West 18 mhz Lower
DL 3811 Vertical FEC ¾ SR 13.235 DR
18.295411 MOD 4:2:0 DVBS QPSK
If you have any questions, please contact Jen Knapp (212)
401-8916.
Facebook and Twitter:
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies please visit
our Facebook page at:
http://www.facebook.com/nasdaqomx
For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaqomx
Webcast:
A live webcast of the NASDAQ Opening Bell will be available at:
http://www.nasdaq.com/about/marketsitetowervideo.asx or
http://social.nasdaqomx.com.
Photos:
To obtain a hi-resolution photograph of the Market Open, please
go to http://www.nasdaq.com/reference/marketsite_events.stm and
click on the market open of your choice.
About NPS Pharmaceuticals, Inc. [NPSP]:
NPS Pharmaceuticals is an outsourcing-based development company
focused on bringing biopharmaceuticals to patients with rare
disorders and few, if any, therapeutic options. The company is
advancing two Phase 3 registration programs, GATTEX(R)
(teduglutide) in short bowel syndrome (SBS) and NPSP558
(parathyroid hormone 1-84 [rDNA origin] injection) in
hypoparathyroidism. NPS' earlier stage pipeline includes two
calcilytic compounds, NPSP790 and NPSP795, with potential
application in rare disorders involving increased calcium receptor
activity, such as autosomal dominant hypocalcemia with
hypercalciuria (ADHH). NPS complements its proprietary programs
with a royalty-based portfolio of products and product candidates
that includes agreements with Amgen, GlaxoSmithKline, Kyowa Hakko
Kirin, Nycomed, and Ortho-McNeil Pharmaceutical.
About NASDAQ OMX:
The NASDAQ OMX Group, Inc. is the world's largest exchange
company. It delivers trading, exchange technology and public
company services across six continents, with more than 3,500 listed
companies. NASDAQ OMX offers multiple capital raising solutions to
companies around the globe, including its U.S. listings market,
NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX first North, and
the U.S. 144A sector. The company offers trading across multiple
asset classes including equities, derivatives, debt, commodities,
structured products and exchange-traded funds. NASDAQ OMX
technology supports the operations of over 70 exchanges, clearing
organizations and central securities depositories in more than 50
countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not
legal entities but describe the common offering from NASDAQ OMX
exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn,
Riga, and Vilnius. For more information about NASDAQ OMX, visit
http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook
(http://www.facebook.com/pages/NASDAQ-OMX/108167527653) and Twitter
(http://www.twitter.com/nasdaqomx).
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Sep 2024 to Oct 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Oct 2023 to Oct 2024